Monoclonal antibodies are considered as one of the most promising biological therapy in the management of various diseases.
Bispecific & Trispecific Antibodies Market Sales Opportunities At USD 25 Billion Says Kuick Research
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Detailed Market Sales & Trends Insight
- Global and Regional Market Analysis
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Ongoing Clinical Trials Assessment by Status, Phase and Region
Download Report: https://www.kuickresearch.com/report-global-bispecific-antibodies-antibody-market-size-blincyto-hemlibra-rybrevant-sales
Monoclonal antibodies are considered as one of the most promising biological therapy in the management of various diseases. Their success is mainly due to their high specificity, homogeneity, and targeted nature. However, the rising incidences of multifactorial diseases has surged the need to enhance the potency of monoclonal antibodies and further extend their mechanism of action. Multispecific antibodies are emerging enhanced counterparts of monoclonal antibodies which have the ability to specifically bind with two or more different antigens. By doing so, they increase their selectivity towards the target cell and also led to enhanced cytotoxic activity.
Bispecific antibodies are most advanced multispecific antibodies which have gained entry into the market. To date, regulatory bodies have approved four bispecific antibodies including Blincyto, Hemlibra, Rybrevant, and Vabysmo. The introduction of these drugs in the market has demonstrated encouraging response. Till 2021, the cumulative sale of bispecific antibodies was analyzed to be around US$ 9 Billion. Their robust sales in the market have drawn the interest from several pharmaceutical giants to actively invest in this segment. Several bispecific antibody constructs are present in clinical developments which are expected to launch in market during the forecast period. As per our analysis, it is estimated that 4-6 bispecific antibodies will gain approval in market in next 5 years.
Presently, no trispecific antibody has been approved by regulatory bodies. However, several trispecific antibodies have entered the initial stages of clinical development and have shown encouraging preliminary results. The major drugs in the clinical pipeline include GTB3550, GTB4550, HPN424, SAR443216, HPN217, and several others. HPN328 developed by Harpoon Therapeutics is TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities. US FDA has granted orphan drug designation for HPN328 for the treatment of small cell lung cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population.
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report: https://www.kuickresearch.com/report-trispecific-antibody-antibodies-market-clinical-trials-development-companies
Although bispecific and trispecific antibodies have entered the clinical development, tetra specific antibodies are still present at very nascent stage. Tetra specific antibodies have the ability to bind to four different receptors simultaneously. Although several manufacturing and stability challenges are associated with their development, the advancement in the field of technology will led to development of these next generation antibody constructs. It is believed that the entry of tetra specific antibodies will transform the overall paradigm of chronic therapies. Systimmune has developed three tetra specific antibodies namely GNC-038 (CD3×41BB×PD-L1×CD19), GNC-039 (CD3×41BB×PD-L1×EGFRvIII), and GNC-035 (CD3×41BB×PD-L1×ROR1) which are present in preclinical stages for the management of wide range of cancers including leukemia, glioblastoma, lymphoma, and other solid tumors.
The encouraging response of antibody therapeutics has propelled the research and development investments in this domain. The major key players in the market include Amgen, Gilead Science, Roche, Zai Lab, Beigene, Akeso, Innovent Biologics, and Novartis. It is expected that the number of products in the market will almost triple in next 10 years.
As per the analysis conducted, it is estimated that the multispecific antibody therapeutics market is expected to surpass US$ 25 Billion by 2028. The high adoption to sedentary lifestyle and increase in prevalence of chronic disease associated with high demand of targeted therapies major driving factor to the growth of market. Further, trends and opportunities coupled within the market i.e. government favorable policies, reimbursement policies, and many others are tending to drive the growth of the market. Moreover, novel alliances including collaboration, partnerships, or joint ventures developed by major key players of the market and local manufacturers are estimated to be playing important role for delivering tremendous opportunities for the researchers, patients, stakeholders and the payers during the forecast period.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366